MarketCapExport financials
Recro Pharma (REPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Recro Pharma Balance Sheet 2023-2011 | REPH
Brief balance sheet overview of Recro Pharma
The comparison uses five available annual reports from the 2019–2023 interval.
Assets added +38.9%, reaching $153.5 million from $110.5 million five periods earlier; annual growth near 8.6% remained solid.
Assets outpaced liabilities, +38.9% versus -19.1%. Dependence on external funding declined.
The share of internal funding stands at 38.2% versus -6.1% initially, providing a reasonable foundation.
Negative net debt of -$6.7 million means cash holdings are larger than debt obligations.
The cash share moved from 17.3% to 5.3%. A higher figure generally provides more room in an adverse scenario.
The balance sheet carries negative retained earnings of -$278.9 million. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Recro Pharma has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Recro Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.65 M | 17.1 M | 71.3 M | 84.5 M | 91.3 M | 25.7 M | -7.39 M | -40.1 M | 9.98 M | -19.7 M | -188 K | 10.1 M | 8.14 M |
Long Term Debt |
339 K | 31 M | 95.5 M | 108 M | 110 M | 64.2 M | 53.6 M | 22.2 M | 25.2 M | - | - | - | - |
Long Term Debt Current |
1.1 M | 1.08 M | 1.06 M | 145 K | 148 K | - | - | 2.24 M | 4.52 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 111 M | 146 M | 107 M | 95.1 M | 88.9 M | - | - | 5.44 M | 5.03 M |
Total Current Liabilities |
50 M | 22.8 M | 17.7 M | 7.8 M | 6.48 M | 29 M | 49.9 M | 16.3 M | 9.49 M | 1.45 M | 12.9 M | - | - |
Total Liabilities |
94.8 M | 97.6 M | 118 M | 118 M | 117 M | 175 M | 157 M | 111 M | 98.3 M | 1.45 M | 12.9 M | 15.7 M | 13.6 M |
Deferred Revenue |
543 K | 2.21 M | 2.31 M | 1.45 M | 337 K | 66 K | 546 K | 418 K | - | - | - | - | - |
Retained Earnings |
-279 M | -266 M | -246 M | -234 M | -207 M | 2.82 M | -111 M | -61.3 M | -31.1 M | -34.1 M | -18 M | -15.6 M | -13.6 M |
Total Assets |
153 M | 157 M | 160 M | 103 M | 110 M | 155 M | 186 M | 183 M | 139 M | 20.4 M | 851 K | 154 K | 25.7 K |
Cash and Cash Equivalents |
8.1 M | 15 M | 25.2 M | 23.8 M | 19.1 M | 38.5 M | 61 M | 64.5 M | 19.8 M | 19.7 M | 13 K | - | - |
Book Value |
58.7 M | 59.9 M | 42.1 M | -14.1 M | -6.71 M | -19.5 M | 28.8 M | 71.6 M | 40.4 M | 18.9 M | -12.1 M | -15.6 M | -13.6 M |
Total Shareholders Equity |
58.7 M | 59.9 M | 42.1 M | -14.1 M | -6.71 M | -19.5 M | 28.8 M | 71.6 M | 40.4 M | 18.9 M | -18 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Recro Pharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
27.4 M | 31 M | 30.5 M | 31 M | 95.5 M | 94.4 M | 93.2 M | 92.1 M | 91 M | 89.8 M | 88.9 M | 108 M | 108 M | 109 M | 109 M | 110 M | 109 M | 107 M | 106 M | 64.2 M | 54.7 M | 54.3 M | 54 M | 53.6 M | 24.9 M | 22.7 M | 22.7 M | 22.2 M | 22.7 M | 22.2 M | 22.6 M | 25.2 M | 24.4 M | 36.5 M | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
93.3 M | 94.4 M | 94 M | 97.6 M | 116 M | 116 M | 113 M | 118 M | 113 M | 96 M | 98.3 M | 118 M | 124 M | 123 M | 119 M | 117 M | 188 M | 181 M | 200 M | 175 M | 162 M | 156 M | 154 M | 157 M | 119 M | 113 M | 112 M | 111 M | 105 M | 102 M | 100 M | 98.3 M | 106 M | 115 M | 2.58 M | 1.45 M | 1.92 M | 1.34 M | 825 K | 12.9 M | 12.9 M | 12.9 M | 12.9 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.31 M | 1.28 M | 1.76 M | 2.21 M | 2.37 M | 2.22 M | 1.84 M | 2.31 M | 2.32 M | 1.07 M | 1.4 M | 1.45 M | 1.34 M | 1.73 M | 786 K | 337 K | 775 K | 637 K | 548 K | 66 K | 302 K | 225 K | 818 K | 546 K | 563 K | 518 K | 796 K | 418 K | 747 K | 418 K | 418 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-278 M | -274 M | -270 M | -266 M | -256 M | -253 M | -250 M | -246 M | -243 M | -240 M | -241 M | -234 M | -223 M | -221 M | -215 M | -207 M | -197 M | -193 M | -190 M | -188 M | -147 M | -134 M | -121 M | -111 M | -87.3 M | -78.2 M | -69.4 M | -61.3 M | -50.9 M | -45.5 M | -37.6 M | -31.1 M | -41.7 M | -39.5 M | -38.2 M | -34.1 M | -34.1 M | -34.1 M | -34.1 M | -18 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
152 M | 149 M | 150 M | 157 M | 151 M | 153 M | 152 M | 160 M | 158 M | 122 M | 89.6 M | 103 M | 109 M | 107 M | 107 M | 110 M | 168 M | 162 M | 181 M | 155 M | 176 M | 180 M | 178 M | 186 M | 169 M | 170 M | 176 M | 183 M | 146 M | 134 M | 135 M | 139 M | 135 M | 130 M | 17.9 M | 20.4 M | 24.1 M | 28.1 M | 30.2 M | 851 K | 851 K | 851 K | 851 K | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
8.16 M | 4.7 M | 6.29 M | 15 M | 11.6 M | 15.5 M | 15.3 M | 25.2 M | 23.5 M | 45.7 M | 11.6 M | 23.8 M | 21.5 M | 22.8 M | 19.9 M | 19.1 M | 37.9 M | 30.4 M | 46 M | 38.5 M | 35.8 M | 48.9 M | 46.3 M | 61 M | 11.8 M | 8.73 M | 19.5 M | 64.5 M | 24.8 M | 14.8 M | 14.9 M | 19.8 M | 28.3 M | 15.7 M | 16.6 M | 19.7 M | 23.9 M | 27.8 M | 29.9 M | 13 K | 12.8 K | 12.8 K | 12.8 K | 53.3 K | - | - | - | - | - | - | - |
Book Value |
58.3 M | 54.3 M | 56 M | 59.9 M | 35.2 M | 37.3 M | 39.2 M | 42.1 M | 44.5 M | 26.4 M | -8.72 M | -14.1 M | -15.1 M | -15.4 M | -12.2 M | -6.71 M | -19.9 M | -18.7 M | -19 M | -19.5 M | 13.5 M | 24.5 M | 24.6 M | 28.8 M | 49.6 M | 57 M | 64.4 M | 71.6 M | 40.6 M | 31.3 M | 35 M | 40.4 M | 28.4 M | 14.7 M | 15.3 M | 18.9 M | 22.2 M | 26.8 M | 29.4 M | -12.1 M | -12.1 M | -12.1 M | -12.1 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
58.3 M | 54.3 M | 56 M | 59.9 M | 35.2 M | 37.3 M | 39.2 M | 42.1 M | 44.5 M | 26.4 M | -8.72 M | -14.1 M | -15.1 M | -15.4 M | -12.2 M | -6.71 M | -19.9 M | -18.7 M | -19 M | -19.5 M | 13.5 M | 24.5 M | 24.6 M | 28.8 M | 49.6 M | 57 M | 64.4 M | 71.6 M | 40.6 M | 31.3 M | 35 M | 40.4 M | 28.4 M | 14.7 M | 15.3 M | 18.9 M | 22.2 M | 26.8 M | 29.4 M | -18 M | -18 M | -18 M | -18 M | -15.6 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Recro Pharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
France
Canada
China
Irlanda
Schweden
